Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ponesimod: Phase III delayed

Actelion disclosed in its 1H13 earnings that it would not start Phase III trials evaluating ponesimod to treat

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE